| Medical and Health Sciences | 2021-2025 | 194 | US 73 | 99.96 |
| Cardiology and Cardiovascular Medicine | Lifetime | 359 | US 207 | 99.53 |
| Nephrology | Lifetime | 83 | US 46 | 99.43 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 66 | US 38 | 99.73 |
| Surgery | 2021-2025 | 130 | US 54 | 99.25 |
| Nephrology | 2021-2025 | 44 | US 20 | 98.73 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 682 | US 245 | 91.64 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 439 | US 173 | 87.38 |
| Peripheral Artery Disease Management | Lifetime | 48 | US 36 | 99.45 |
| Chronic Kidney Disease and Diabetes | Lifetime | 49 | US 25 | 99.60 |
| Blood Pressure and Hypertension Studies | Lifetime | 124 | US 55 | 99.51 |
| Dialysis and Renal Disease Management | Lifetime | 93 | US 48 | 99.44 |
| Cardiovascular Function and Risk Factors | Lifetime | 344 | US 198 | 99.34 |
| Cardiovascular Health and Disease Prevention | Lifetime | 246 | US 112 | 98.70 |
| Cardiovascular Health and Risk Factors | Lifetime | 93 | US 56 | 98.41 |
| Renal and Vascular Pathologies | Lifetime | 249 | US 146 | 98.26 |
| Heart Failure Treatment and Management | Lifetime | 477 | US 232 | 98.26 |
| Cardiovascular Disease and Adiposity | Lifetime | 633 | US 313 | 96.96 |
| Lipoproteins and Cardiovascular Health | Lifetime | 977 | US 392 | 96.41 |
| Diabetic Foot Ulcer Assessment and Management | Lifetime | 853 | US 352 | 93.93 |
| Diagnosis and Treatment of Venous Diseases | Lifetime | 729 | US 262 | 92.18 |
| Potassium and Related Disorders | Lifetime | 505 | US 243 | 91.37 |
| Biomarkers in Disease Mechanisms | Lifetime | 447 | US 123 | 87.78 |
| GDF15 and Related Biomarkers | Lifetime | 626 | US 200 | 79.61 |
| Peripheral Artery Disease Management | 2021-2025 | 3 | US 3 | 99.65 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 17 | US 5 | 99.55 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 27 | US 5 | 98.27 |
| Chronic Kidney Disease and Diabetes | 2021-2025 | 37 | US 15 | 98.95 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 25 | US 20 | 98.01 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 217 | US 96 | 98.34 |
| Cerebrovascular and Carotid Artery Diseases | 2021-2025 | 156 | US 56 | 97.85 |
| Heart Failure Treatment and Management | 2021-2025 | 159 | US 66 | 98.07 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 263 | US 75 | 91.17 |
| Dialysis and Renal Disease Management | 2021-2025 | 309 | US 68 | 94.40 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 410 | US 128 | 92.29 |
| Diabetic Foot Ulcer Assessment and Management | 2021-2025 | 268 | US 71 | 91.03 |
| Acute Myocardial Infarction Research | 2021-2025 | 717 | US 174 | 92.02 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 73 | US 19 | 85.20 |
| Diagnosis and Treatment of Venous Diseases | 2021-2025 | 174 | US 65 | 89.16 |
| Parathyroid Disorders and Treatments | 2021-2025 | 533 | US 142 | 86.13 |
| Cardiac Health and Mental Health | 2021-2025 | 800 | US 239 | 83.23 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 252 | US 74 | 78.83 |
| GDF15 and Related Biomarkers | 2021-2025 | 264 | US 79 | 70.32 |
| Fibroblast Growth Factor Research | 2021-2025 | 594 | US 179 | 65.56 |
| Magnesium in Health and Disease | 2021-2025 | 736 | US 150 | 34.65 |
